New, Small, Cheap, MRI, could better test for recurrence

There is also new trial research, shared on a bulletin from my Cancer Center in Seattle, that when Breast cancer metastasizes to the bones, there hasn't been a reliable way to tell whether treatments people are on are working, when mainly in the bones. Patients may continue with ineffective treatments longer than necessary. There is a trial that followed 138 patients over 3-5 years that has shown that with FDG-PET/CT imaging (using sugar as a contrast), docs can predict progression-free survival after just 12 weeks. The scan shows how active cancer cells are, not just showing their shape or size.....whether the treatment is working, is an effective one. Sounds like a good development.

There is also new trial research, shared on a bulletin from my Cancer Center in Seattle, that when Breast cancer metastasizes to the bones, there hasn't been a reliable way to tell whether treatments people are on are working, when mainly in the bones. Patients may continue with ineffective treatments longer than necessary. There is a trial that followed 138 patients over 3-5 years that has shown that with FDG-PET/CT imaging (using sugar as a contrast), docs can predict progression-free survival after just 12 weeks. The scan shows how active cancer cells are, not just showing their shape or size.....whether the treatment is working, is an effective one. Sounds like a good development.

Hi! @jardinera25 :

Thanks for sharing such exciting info regarding this new research trial from your cancer center in Seattle!

Please keep us posted as it progresses as the time goes by to help us all:)

Thanks again!

@lifetraveler and @coley,
I went ahead and researched online to see if I could find more on this study, and there was much more specific information! This looks like a game changer in finding the right treatment for those with bone metastasis, much more quickly.
"The study’s lead investigator, Jennifer M. Specht, MD, a medical oncologist at the University of Washington and Fred Hutch Cancer Center, presented the results of the FEATURE trial (EA1183, NCT04316117) at the 2025 San Antonio Breast Cancer Symposium. Heather A. Jacene, MD, a nuclear medicine physician from Brigham and Women’s Hospital and Dana-Farber Cancer Institute, co-led the trial with Dr. Specht." It also said "This multi-center trial involved investigators and patients at 35 hospitals and cancer centers across the United States and in Ireland. It received support from the National Cancer Institute..." So it's not just at my cancer center.
https://ecog-acrin.org/press-release-an-ecog-acrin-imaging-study-solves-a-long-standing-gap-in-metastatic-breast-cancer-research-and-care-accurately-measuring-treatment-response-in-patients-with-bone-metastases/
Looks like you have to highlight, copy & paste onto internet search bar to read the article.